Nadofaragene firadenovec (Adstiladrin)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

From the NCI Drug Dictionary: A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.

Diseases for which it is used

History of changes in FDA indication

  • 2022-12-16: Initial approval for adult patients with high-risk BCG vaccine unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. (Based on rAd-IFN-CS-003)

Also known as

  • Code name: SCH-721015
  • Generic name: nadofaragene firadenovec-vncg
  • Brand name: Adstiladrin, Instiladrin